Clinical breast cancer 2006-12
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Related Questions
New answer by Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR (March 8, 2017)
Genomic assays may be helpful and it is being used in lot of institutions.
Recent SABCS abstract comparing various platforms from TransATAC came up with some inte...